CAR-T science and manufacturing: from concept to therapy

Since 2013, the CliniMACS Prodigy® platform has enabled the development of next-generation cell therapies.

Since 2013, Miltenyi’s technology has supported the development of next-generation cell therapies and extensive basic research in cell biology. Today, this expertise enables Miltenyi Biomedicine to explore novel therapeutic concepts with the aim of advancing efficacy, safety, and accessibility for patients with high unmet needs.